![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C25H30O2 |
Molar mass | 362.513 g·mol−1 |
3D model (JSmol) | |
| |
|
KM-233 is asynthetic cannabinoid drug which is astructural analog of Δ8-tetrahydrocannabinol (THC), the less active but more stableisomer of the active component ofCannabis. KM-233 differs from Δ8-THC by thepentylside chain being replaced by a 1,1-dimethylbenzyl group. It has high binding affinityin vitro for both theCB1 andCB2 receptors, with a CB2 affinity of 0.91 nM and 13-fold selectivity over the CB1 receptor.[1] In animal studies, it has been found to be a potential treatment forglioma, a form of brain tumor.[2] Many related analogues are known where the 1,1-dimethylbenzyl group is substituted or replaced by other groups, with a fairly well establishedstructure-activity relationship.[3][4][5][6][7]
![]() | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |